Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for LeMaitre Vascular, Inc. (NASDAQ: LMAT), a Delaware-incorporated medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Through these filings, investors can review the company’s formal disclosures on operations, financial condition, risk factors, and governance.
LeMaitre’s SEC submissions include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present detailed financial statements, segment information, and discussions of risks such as competition, supplier dependence, regulatory compliance for devices and tissue products, international operations, product defects or recalls, litigation, and intellectual property protection. Current reports on Form 8-K, such as those referenced in the provided materials, disclose events like quarterly financial results, board decisions, and other material developments.
The company also uses its filings to describe capital markets activities, including the listing of its common stock on The Nasdaq Global Market under the symbol LMAT, the existence of convertible senior notes, dividend declarations, and share repurchase authorizations. These documents complement the non-GAAP metrics discussed in press releases by providing reconciliations and additional context for measures such as organic sales growth, adjusted margins, and EBITDA.
On Stock Titan, LeMaitre’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents like 10-Ks and 10-Qs, highlight important changes from prior periods, and clarify the implications of 8-K disclosures. Users can also review insider-related filings such as Forms 3, 4, and 5, where available, to track transactions by directors and officers. This combination of raw filings and AI-generated insights allows readers to understand LMAT’s regulatory record and financial reporting more efficiently.
LeMaitre Vascular director Martha Shadan reported equity-based compensation awards, not open-market trades. On March 26, 2026, she was granted several small blocks of Dividend Equivalent Rights, each tied to existing restricted stock unit and performance share unit awards granted in December 2023, 2024, and 2025.
Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying stock awards. All transactions are coded as awards or other acquisitions, with no reported share purchases or sales in the market.
LEMAITRE VASCULAR INC director Bridget A. Ross reported compensation-related awards of dividend equivalent rights tied to existing equity grants. On March 26, 2026, she acquired several small blocks of dividend equivalent rights, each economically equivalent to one share of common stock and linked to prior restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. These rights vest proportionately with the underlying awards and reflect routine equity compensation accruals rather than open-market trading.
LeMaitre Vascular director John James O'Connor reported grants of dividend equivalent rights linked to existing stock awards. On March 26, 2026, he acquired several small blocks of Dividend Equivalent Rights, each economically equivalent to one share of LeMaitre common stock.
The rights accrued on previously granted restricted stock unit and performance share unit awards from December 8, 2023, December 6, 2024, and December 10, 2025, and will vest proportionately with those underlying awards. These are compensation-related accruals rather than open‑market share purchases or sales.
LeMaitre Vascular director John A. Roush reported grants of dividend equivalent rights tied to prior equity awards. On March 26, 2026, he acquired several small fractional awards of Dividend Equivalent Rights, each economically equal to one share of LeMaitre Vascular common stock.
The rights accrued on restricted stock unit and performance share unit awards originally granted on December 8, 2023, December 6, 2024, and December 10, 2025, and they vest proportionately with those underlying awards. These are compensation-related accruals rather than open-market stock purchases or sales.
LEMAITRE VASCULAR INC director Lawrence J. Jasinski reported routine compensation-related grants of dividend equivalent rights. On March 26, 2026, he acquired several small fractional awards of dividend equivalent rights linked to existing restricted stock unit and performance share unit grants from December 8, 2023, December 6, 2024, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the underlying stock or performance awards. These are non-cash, derivative awards and do not represent any open-market share purchases or sales.
LeMaitre Vascular director Joseph P. Pellegrino Jr. reported multiple awards of dividend equivalent rights on derivative securities. On March 26, 2026, he acquired several small grants of Dividend Equivalent Rights, each tied to existing restricted stock unit and performance share unit awards.
Each dividend equivalent right is described as the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying equity awards granted in 2022, 2023, and 2024–2025. These are compensation-related accruals, with no open-market purchases or sales reported in this filing.
LeMaitre Vascular (LMAT) President and Director David B. Roberts reported compensation-related grants of dividend equivalent rights on derivative awards. On March 26, 2026, he acquired multiple small blocks of Dividend Equivalent Rights, each economically equal to one share of common stock and priced at $0.0000 per right.
The footnotes explain these rights accrued on previously granted restricted stock units and performance share units from awards dated December 12, 2022, December 8, 2023, December 6, 2024, February 18, 2025, and December 10, 2025, and vest proportionately with those awards. No open‑market buys or sells were reported; this filing reflects routine equity-based compensation accrual rather than trading activity.
LeMaitre Vascular Senior Vice President of Operations Trent G. Kamke reported seven acquisitions of Dividend Equivalent Rights on March 26, 2026. Each right is economically equivalent to one share of LeMaitre common stock and is tied to previously granted restricted stock unit and performance share unit awards from 2022, 2023, 2024 and 2025, vesting in step with those underlying awards. These entries reflect routine, compensation-related accruals rather than open-market trading.
LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.
LeMaitre Vascular Chief Financial Officer Dorian Paul LeBlanc received additional dividend equivalent rights tied to existing restricted stock unit awards. On March 26, 2026, he was granted 2.0948 dividend equivalent rights related to an RSU award granted on March 10, 2025 and 2.6670 rights related to an RSU award granted on December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying RSUs. Following these awards, his holdings from these grants increased to 11.4217 and 2.6670 dividend equivalent rights, respectively.
LeMaitre Vascular’s Chairman and CEO, George W. LeMaitre, reported routine compensation-related awards rather than market trades. On March 26, 2026, he acquired several blocks of dividend equivalent rights, each economically equal to one share of LeMaitre Vascular common stock.
The rights accrued automatically on earlier restricted stock unit and performance share unit awards granted in December 2022, 2023, and 2024, and they will vest proportionately with those underlying awards. No open-market buying or selling occurred, and the transactions do not change cash holdings.